Novartis Pharma AG: Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer

Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker

Related Keywords

United States ,America ,American ,Isabella Zinck ,Amy Wolf ,Nicole Zinsli Somm ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Promacta Revolade ,Alina Levchuk ,American Society Of Clinical Oncology ,Novartis Institutes For Biomedical Research ,Twitter ,Astex Pharmaceuticals ,European Hematology Association ,Novartis Oncology Communications ,Novartis Us External Communications ,Novartis External Communications ,Novartis ,Exchange Commission ,Innovative Medicines International ,Clinical Oncology ,Annual Meeting ,Marie France Tschudin ,Chief Commercial Officer ,With Hormone Receptor Positive ,Human Epidermal Growth Factor Receptor ,Advanced Breast Cancer ,Next Generation Sequencing ,Novartis Institutes ,Biomedical Research ,Advanced Accelerator Applications ,Dharma ,Data ,Disco ,Showcase ,Latest ,Ncology ,Research ,Innovation ,Ncluding ,Breast ,Prostate ,Dancer ,